



Curriculum Vitae

Personal information **Violaine Closson Carella**

Work experience

1. Employer: ANSM
 - Start date: 062016
 - End date:
 - Position: Cell and Gene Therapy Referent
 - Activities: Regulation of Advanced Therapeutic Medicinal Products at the French regulatory agency (ANSM)
 - Country: France
2. Employer: ANSM
 - Start date: 062012
 - End date: 032015
 - Position: Inspector
 - Activities: Inspection of cell and tissue establishments
 - Country: France
3. Employer: ANSM
 - Start date: 032015
 - End date: 052016
 - Position: Head of Department of Advanced Therapy Medicinal Products/ Organ, Tissue and Cell Preparations
 - Activities: Regulation of medicinal products and Advanced Therapeutic Medicinal Products at the French regulatory agency (ANSM)
 - Country: France
4. Employer: HRA_Pharma
 - Start date: 082011
 - End date: 012012
 - Position: Regulatory Affairs Pharmacist
 - Activities:
 - Country: France
5. Employer: Orphan Europe S.A.R. L.
 - Start date: 062007
 - End date: 072011
 - Position: International Regulatory Affairs Project Manager
 - Activities: Management of marketing authorisations of orphan drugs
 - Country: France
6. Employer: Immuno_Designed Molecules S.A.
 - Start date: 122001
 - End date: 062007
 - Position: Cell therapy production manager
 - Activities: Production of cell therapy products for clinical trials
 - Country: France
7. Employer: Columbia University
 - Start date: 051998
 - End date: 102001
 - Position: Associate Research Scientist
 - Activities: Role of Notch 4 on endothelial cells and angiogenesis
 - Country: United States
8. Employer: INSERM
 - Start date: 021997
 - End date: 011998
 - Position: Research Engineer
 - Activities:
 - Country: France

Education and training

1. Subject: University of Paris VII
 - Start date: 111989
 - End date: 101995
 - Qualification: Ph. D in Science: Human Genetics
 - Organisation: Expression and function of two ras-related proteins in normal and tumoral human tissues
 - Country: France
2. Subject: University of Paris V
 - Start date: 111989
 - End date: 051995
 - Qualification: Ph. D in Specialized Studies of "Clinical Pharmacy"
 - Organisation:
 - Country: France
3. Subject: University of Paris V
 - Start date: 101983
 - End date: 121994
 - Qualification: Ph. D in Pharmacy

- Organisation:
- Country:

Additional information

Publications

1_Uyttendaele H, Closson V, Wu G, Roux F, Weinmaster G, Kitajewski J (2000). Notch4 and Jagged_1 induce microvessel differentiation of rat brain endothelial cells. *Microvasc Res* 60(2):91_103. 2_Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH, Stark KL, Gridley T (2000). Notch signaling is essential for vascular morphogenesis in mice. *Genes Dev* 14(11):1343_52. 3_Zalcman G, Closson V, Camonis J, Honoré N, Rousseau_Merck MF, Tavitian A, Olofsson B (1996) . RhoGDI_3 is a new GDP dissociation inhibitor (GDI). Identification of a non_cytosolic GDI protein interacting with the small GTP_binding proteins RhoB and RhoG. *J Biol Chem* 271(48):30366_74. 4_Zalcman G, Closson V, Linares_Cruz G, Lerebours F, Honoré N, Tavitian A, Olofsson B (1995) . Regulation of Ras_related RhoB protein expression during the cell cycle. *Oncogene* 18;10(10):1935_45. 5_de Cremoux P, Gauville C, Closson V, Linares G, Calvo F, Tavitian A, Olofsson B (1994). EGF modulation of the ras_related rhoB gene expression in human breast_cancer cell lines. *Int J Cancer* 59(3):408_15. 6_Culine S, Honore N, Closson V, Droz JP, Extra JM, Marty M, Tavitian A, Olofsson B (1994). A small GTP_binding protein is frequently overexpressed in peripheral blood mononuclear cells from patients with solid tumours. *Eur J Cancer* 30A(5):670_4. 7_Culine S, Honore N, Closson V, Lang P, Bertoglio J, Laroche L, Bussel A, Racadot E, Hovnanian A, Dubertret L, et al (1993). A CD2+ subset of non_malignant peripheral blood lymphocytes from patients with Sézary syndromes overexpress the low_molecular_weight GTP_binding protein Rab2. *Leukemia* 7(4):601_8. 8_Culine S, Honoré N, Closson V, Lang P, Bertoglio J, Tavitian A, Olofsson B (1993). A possible role for the Ras_related Rab2 protein in the immunological events associated with hematological malignancies. *Nouv Rev Fr Hematol* 35(1):41_4. Review.

Projects

Memberships

Member of the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA) since 2015

Other Relevant Information